<PubmedArticle>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">22075481</PMID>
<DateCompleted>
<Year>2012</Year>
<Month>10</Month>
<Day>16</Day>
</DateCompleted>
<DateRevised>
<Year>2015</Year>
<Month>11</Month>
<Day>19</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1399-3003</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>39</Volume>
<Issue>6</Issue>
<PubDate>
<Year>2012</Year>
<Month>Jun</Month>
</PubDate>
</JournalIssue>
<Title>The European respiratory journal</Title>
<ISOAbbreviation>Eur. Respir. J.</ISOAbbreviation>
</Journal>
<ArticleTitle>Bronchoscopic thermal vapour ablation therapy in the management of heterogeneous emphysema.</ArticleTitle>
<Pagination>
<MedlinePgn>1326-33</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1183/09031936.00092411</ELocationID>
<Abstract>
<AbstractText>The need for a less invasive procedure than surgical lung volume reduction that can produce consistent improvements with reduced morbidity remains a medical goal in patients with emphysema. We sought to determine the effect of bronchoscopic thermal vapour ablation (BTVA) on lung volumes and outcomes in patients with emphysema. 44 patients with upper lobe-predominant emphysema were treated unilaterally with BTVA. Entry criteria included: age 40-75 yrs, forced expiratory volume in 1 s (FEV(1)) 15-45% predicted, previous pulmonary rehabilitation and a heterogeneity index (tissue/air ratio of lower lobe/upper lobe) from high-resolution computed tomography (HRCT) ≥ 1.2. Changes in FEV(1), St George's Respiratory Questionnaire (SGRQ), 6-min walk distance (6 MWD), modified Medical Research Council (mMRC) dyspnoea score, and hyperinflation were measured at baseline, and 3 and 6 months post-BTVA. At 6 months, mean ± SE FEV(1) improved by 141 ± 26 mL (p&lt;0.001) and residual volume was reduced by 406 ± 113 mL (p&lt;0.0001). SGRQ total score improved by 14.0 ± 2.4 points (p&lt;0.001), with 73% improving by ≥ 4 points. Improvements were observed in 6 MWD (46.5 ± 10.6 m) and mMRC dyspnoea score (0.9 ± 0.2) (p&lt;0.001 for both). Lower respiratory events (n=11) were the most common adverse event and occurred most often during the initial 30 days. BTVA therapy results in clinically relevant improvements in lung function, quality of life and exercise tolerance in upper lobe predominant emphysema.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Snell</LastName>
<ForeName>Gregory</ForeName>
<Initials>G</Initials>
<AffiliationInfo>
<Affiliation>Allergy Immunology and Respiratory Medicine, The Alfred Hospital, 55 Commercial Road, Melbourne, Victoria 3004, Australia. g.snell@alfred.org.au</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Herth</LastName>
<ForeName>Felix J F</ForeName>
<Initials>FJ</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Hopkins</LastName>
<ForeName>Peter</ForeName>
<Initials>P</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Baker</LastName>
<ForeName>Kimberley M</ForeName>
<Initials>KM</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Witt</LastName>
<ForeName>Christian</ForeName>
<Initials>C</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Gotfried</LastName>
<ForeName>Mark H</ForeName>
<Initials>MH</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Valipour</LastName>
<ForeName>Arschang</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Wagner</LastName>
<ForeName>Manfred</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Stanzel</LastName>
<ForeName>Franz</ForeName>
<Initials>F</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Egan</LastName>
<ForeName>Jim J</ForeName>
<Initials>JJ</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Kesten</LastName>
<ForeName>Steven</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Ernst</LastName>
<ForeName>Armin</ForeName>
<Initials>A</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<DataBankList CompleteYN="Y">
<DataBank>
<DataBankName>ClinicalTrials.gov</DataBankName>
<AccessionNumberList>
<AccessionNumber>NCT01041586</AccessionNumber>
<AccessionNumber>NCT01102712</AccessionNumber>
</AccessionNumberList>
</DataBank>
</DataBankList>
<PublicationTypeList>
<PublicationType UI="D016430">Clinical Trial</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2011</Year>
<Month>11</Month>
<Day>10</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Eur Respir J</MedlineTA>
<NlmUniqueID>8803460</NlmUniqueID>
<ISSNLinking>0903-1936</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D055011">Ablation Techniques</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000379">methods</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001999">Bronchoscopy</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000379">methods</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004417">Dyspnea</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000601">surgery</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017079">Exercise Tolerance</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011013">Pneumonectomy</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000379">methods</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011656">Pulmonary Emphysema</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000601">surgery</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011788">Quality of Life</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012129">Respiratory Function Tests</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011795">Surveys and Questionnaires</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016896">Treatment Outcome</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
<PubMedPubDate PubStatus="entrez">
<Year>2011</Year>
<Month>11</Month>
<Day>15</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed">
<Year>2011</Year>
<Month>11</Month>
<Day>15</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline">
<Year>2012</Year>
<Month>10</Month>
<Day>17</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
<ArticleId IdType="pubmed">22075481</ArticleId>
<ArticleId IdType="pii">09031936.00092411</ArticleId>
<ArticleId IdType="doi">10.1183/09031936.00092411</ArticleId>
</ArticleIdList>
</PubmedData>
</PubmedArticle>